Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: Clinical impact and therapeutic options

International Journal of Antimicrobial Agents

Volumn 39, Issue 2, 2012, Pages 105-114

  Kempf, Marie ^a   Rolain, Jean Marc ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Antibiotic therapy; Carbapenemase; Colistin; Cystic fibrosis; Fitness cost

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BACTERIUM LIPOPOLYSACCHARIDE; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; OXACILLIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULBACTAM; SULTAMICILLIN; TETRACYCLINE; TICARCILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DRUG FATALITY; EPIDEMIC; EUROPE; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; MOLECULAR MECHANICS; MOLECULAR TYPING; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 84855484468     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.10.004     Document Type: Short Survey

References (122)

1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
2. Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect 2005;11:868-73.
3. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-9. (Pubitemid 43271386)
4. Oncul O, Keskin O, Acar HV, Kucukardali Y, Evrenkaya R, Atasoyu EM, et al. Hospital-acquired infections following the 1999 Marmara earthquake. J Hosp Infect 2002;51:47-51. (Pubitemid 37554842)
5. Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, et al. An outbreak of multidrug-resistant Acinetobacter baumannii - calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007;44:1577-84. (Pubitemid 46871504)
6. Coelho J, Woodford N, Turton J, Livermore DM. Multiresistant Acinetobacter in the UK: how big a threat? J Hosp Infect 2004;58:167-9. (Pubitemid 39462582)
7. Lockhart SR, Abramson MA, Beekmann SE, Gallagher G, Riedel S, Diekema DJ, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:3352-9. (Pubitemid 47585661)
8. Paton R, Miles RS, Hood J, Amyes SG, Miles RS, Amyes SG. ARI 1: β-lactamase-mediated imipenem resistance in Acinetobacter baumannii. Int J Antimicrob Agents 1993;2:81-7.
9. Richet HM, Mohammed J, McDonald LC, Jarvis WR. Building communication networks: international network for the study and prevention of emerging antimicrobial resistance. Emerg Infect Dis 2001;7:319-22. (Pubitemid 32374353)
10. Lopez-Rojas R, Dominguez-Herrera J, McConnell MJ, Docobo-Perez F, Smani Y, Fernandez-Reyes M, et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 2011;203:545-8.
11. Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis 2009;65:188-91.
12. Park YK, Jung SI, Park KH, Cheong HS, Peck KR, Song JH, et al. Independent emergence of colistin-resistant Acinetobacter spp. isolates from Korea. Diagn Microbiol Infect Dis 2009;64:43-51.
13. Rolain JM, Roch A, Castanier M, Papazian L, Raoult D. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011;204:1146-7.
14. López-Rojas R, Jiménez-Mejías ME, Lepe JA, Pachón J. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 2011;204:1147-8.
15. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum β-lactamase VEB-1-producing isolates of Acinetobacter baumannii in a French hospital. J Clin Microbiol 2003;41:3542-7. (Pubitemid 36994680)
16. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, Poirel L, et al. Comparative genomics of multidrug resistance in Acinetobacter baumannii. PLoS Genet 2006;2:e7.
17. Vallenet D, Nordmann P, Barbe V, Poirel L, Mangenot S, Bataille E, et al. Comparative analysis of Acinetobacters: three genomes for three lifestyles. PLoS One 2008;3:e1805.
18. Nigro SJ, Post V, Hall RM. The multiresistant Acinetobacter baumannii European clone I type strain RUH875 (A297) carries a genomic antibiotic resistance island AbaR21, plasmid pRAY and a cluster containing ISAba1-sul2-CR2-strB-strA. J Antimicrob Chemother 2011;66:1928-30.
19. Adams MD, Goglin K, Molyneaux N, Hujer KM, Lavender H, Jamison JJ, et al. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii. J Bacteriol 2008;190:8053-64.
20. Post V, White PA, Hall RM. Evolution of AbaR-type genomic resistance islands in multiply antibiotic-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010;65:1162-70.
21. Hornsey M, Loman N, Wareham DW, Ellington MJ, Pallen MJ, Turton JF, et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother 2011;66:1499-503.
22. Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. J Clin Microbiol 1998;36:1938-41. (Pubitemid 28277780)
23. McDonald LC, Banerjee SN, Jarvis WR. Seasonal variation of Acinetobacter infections: 1987-1996. Nosocomial Infections Surveillance System. Clin Infect Dis 1999;29:1133-7. (Pubitemid 30265629)
24. Berlau J, Aucken HM, Houang E, Pitt TL. Isolation of Acinetobacter spp. including A. baumannii from vegetables: implications for hospital-acquired infections. J Hosp Infect 1999;42:201-4. (Pubitemid 29353735)
25. Berlau J, Aucken H, Malnick H, Pitt T. Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis 1999;18:179-83. (Pubitemid 29527951)
26. Seifert H, Dijkshoorn L, Gerner-Smidt P, Pelzer N, Tjernberg I, Vaneechoutte M. Distribution of Acinetobacter species on human skin: comparison of phenotypic and genotypic identification methods. J Clin Microbiol 1997;35:2819-25. (Pubitemid 27452417)
27. Dijkshoorn L, van Aken E, Shunburne L, van der Reijden TJ, Bernards AT, Nemec A, et al. Prevalence of Acinetobacter baumannii and other Acinetobacter spp. in faecal samples from non-hospitalised individuals. Clin Microbiol Infect 2005;11:329-32. (Pubitemid 40443841)
28. Catalano M, Quelle LS, Jeric PE, Di Martino A, Maimone SM. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J Hosp Infect 1999;42:27-35. (Pubitemid 29240300)
29. Wendt C, Dietze B, Dietz E, Ruden H. Survival of Acinetobacter baumannii on dry surfaces. J Clin Microbiol 1997;35:1394-7. (Pubitemid 27216802)
30. Johnson EN, Burns TC, Hayda RA, Hospenthal DR, Murray CK. Infectious complications of open type III tibial fractures among combat casualties. Clin Infect Dis 2007;45:409-15. (Pubitemid 47204454)
31. Tao C, Kang M, Chen Z, Xie Y, Fan H, Qin L, et al. Microbiologic study of the pathogens isolated from wound culture among Wenchuan earthquake survivors. Diagn Microbiol Infect Dis 2009;63:268-70.
32. La SB, Fournier PE, Brouqui P, Raoult D. Detection and culture of Bartonella quintana, Serratia marcescens, and Acinetobacter spp. from decontaminated human body lice. J Clin Microbiol 2001;39:1707-9. (Pubitemid 32417008)
33. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006;55:1619-29. (Pubitemid 44902023)
34. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother 2003;52:629-35. (Pubitemid 37258424)
35. Rodriguez-Martinez JM, Nordmann P, Ronco E, Poirel L. Extended-spectrum cephalosporinase in Acinetobacter baumannii. Antimicrob Agents Chemother 2010;54:3484-8.
36. Mantengoli E, Rossolini GM. Tn5393d, a complex Tn5393 derivative carrying the PER-1 extended-spectrum β-lactamase gene and other resistance determinants. Antimicrob Agents Chemother 2005;49:3289-96. (Pubitemid 41060573)
37. Poirel L, Naas T, Nordmann P. Genetic support of extended-spectrum β-lactamases. Clin Microbiol Infect 2008;14(Suppl. 1):75-81 [Erratum in: Clin Microbiol Infect 2008;14(Suppl. 5):21-4].
38. Naas T, Coignard B, Carbonne A, Blanckaert K, Bajolet O, Bernet C, et al. VEB-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii, France. Emerg Infect Dis 2006;12:1214-22.
39. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum β-lactamases in Acinetobacter baumannii in Belgium. J Antimicrob Chemother 2006;58:178-82. (Pubitemid 44295003)
40. Pasteran F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, et al. Emergence of PER-2 and VEB-1a in Acinetobacter baumannii strains in the Americas. Antimicrob Agents Chemother 2006;50:3222-4. (Pubitemid 44396446)
41. Jeong SH, Bae IK, Kwon SB, Lee K, Yong D, Woo GJ, et al. Investigation of a nosocomial outbreak of Acinetobacter baumannii producing PER-1 extendedspectrum β-lactamase in an intensive care unit. J Hosp Infect 2005;59:242-8. (Pubitemid 40197787)
42. Litake GM, Ghole VS, Niphadkar KB, Joshi SG. PER-1-type extended-spectrum β-lactamase-producing Acinetobacter baumannii clinical isolates from India. Int J Antimicrob Agents 2009;34:388-9.
43. Naas T, Kernbaum S, Allali S, Nordmann P. Multidrug-resistant Acinetobacter baumannii, Russia. Emerg Infect Dis 2007;13:669-71.
44. Strateva T, Todorova A, Ouzounova-Raykova V, Mitov I. Emergence of a PER-1 extended-spectrum β-lactamase-producing Acinetobacter baumannii clinical isolate in Bulgaria. J Chemother 2008;20:391-2. (Pubitemid 351998907)
45. Szabo D, Szentandrassy J, Juhasz Z, Katona K, Nagy K, Rokusz L. Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumannii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary. Ann Clin Microbiol Antimicrob 2008;7:12.
46. Zhang JP, Zhu W, Tian SF, Chu YZ, Chen BY. Molecular characteristics and resistant mechanisms of imipenem-resistant Acinetobacter baumannii isolates in Shenyang, China. J Microbiol 2010;48:689-94.
47. Bonnin RA, Potron A, Poirel L, Lecuyer H, Neri R, Nordmann P. PER-7, an extended spectrum β-lactamase with increased activity toward broadspectrum cephalosporins in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:2424-7.
48. Bonnin RA, Nordmann P, Potron A, Lecuyer H, Zahar JR, Poirel L. Carbapenemhydrolyzing GES-type extended-spectrum β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:349-54.
49. Moubareck C, Bremont S, Conroy MC, Courvalin P, Lambert T. GES-11, a novel integron-associated GES variant in Acinetobacter baumannii. Antimicrob Agents Chemother 2009;53:3579-81.
50. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2010;65:233-8.
51. Donald HM, Scaife W, Amyes SG, Young HK. Sequence analysis of ARI-1, a novel OXA β-lactamase, responsible for imipenem resistance in Acinetobacter baumannii 6B92. Antimicrob Agents Chemother 2000;44:196-9. (Pubitemid 30010698)
52. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36. (Pubitemid 44151282)
53. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 2010;54:24-38.
54. NDM-1 and armA in clinical isolates of Acinetobacter baumannii from India. J Antimicrob Chemother 2010;65:2253-4.
55. Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009;3:335-41.
56. Kaase M, Nordmann P, Wichelhaus TA, Gatermann SG, Bonnin RA, Poirel L. NDM-2 carbapenemase in Acinetobacter baumannii from Egypt. J Antimicrob Chemother 2011;66:1260-2.
57. Chen Y, Zhou Z, Jiang Y, Yu Y. Emergence of NDM-1-producing Acinetobacter baumannii in China. J Antimicrob Chemother 2011;66:1255-9.
58. Rolain JM, Parola P, Cornaglia G. New Delhi metallo-β-lactamase (NDM-1): towards a new pandemia? Clin Microbiol Infect 2010;16:1699-701.
59. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010;16:112-22.
60. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005;18:306-25.
61. Kusradze I, Diene SM, Goderdzishvili M, Rolain JM. Molecular detection of OXA carbapenemase genes in multidrug-resistant Acinetobacter baumannii isolates from Iraq and Georgia. Int J Antimicrob Agents 2011;38:164-8.
62. Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006;258:72-7.
63. Drissi M, Poirel L, Mugnier PD, Baba AZ, Nordmann P. Carbapenemaseproducing Acinetobacter baumannii, Algeria. Eur J Clin Microbiol Infect Dis 2010;29:1457-8.
64. OXA-23 carbapenemase gene of Acinetobacter baumannii. Emerg Infect Dis 2010;16:35-40.
65. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
66. Adams MD, Nickel GC, Bajaksouzian S, Lavender H, Murthy AR, Jacobs MR, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009;53:3628-34.
67. Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010;54:4971-7.
68. Alhanout K, Brunel JM, Raoult D, Rolain JM. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J Antimicrob Chemother 2009;64:810-4.
69. Alhanout K, Malesinki S, Vidal N, Peyrot V, Rolain JM, Brunel JM. New insights into the antibacterial mechanism of action of squalamine. J Antimicrob Chemother 2010;65:1688-93.
70. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. The insertion sequence ISAba11 is involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. Antimicrob Agents Chemother 2011;55:3022-4.
71. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol 2007;56:165-71.
72. Rodloff AC, Leclercq R, Debbia EA, Canton R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the Tigecycline Evaluation and Surveillance Trial. Clin Microbiol Infect 2008;14:307-14. (Pubitemid 351356520)
73. Dizbay M, Altuncekic A, Sezer BE, Ozdemir K, Arman D. Colistin and tigecycline susceptibility among multidrug-resistant Acinetobacter baumannii isolated from ventilator-associated pneumonia. Int J Antimicrob Agents 2008;32:29-32.
74. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003;24:284-95. (Pubitemid 36538142)
75. Da Silva G, Dijkshoorn L, van der Reijden T, van Strijen B, Duarte A. Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II. Clin Microbiol Infect 2007;13:190-5. (Pubitemid 46115656)
76. Kresken M, Becker K, Seifert H, Leitner E, Körber-Irrgang B, von Eiff C, et al. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany. Eur J Clin Microbiol Infect Dis 2011;30:1095-103.
77. Oteo J, García-Estébanez C, Migueláñez S, Campos J, Martí S, Vila J, et al. Genotypic diversity of imipenem resistant isolates of Acinetobacter baumannii in Spain. J Infect 2007;55:260-6. (Pubitemid 47244917)
78. Unal S, Garcia-Rodriguez JA. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005;53:265-71. (Pubitemid 41796897)
79. Nordmann P, Picazo JJ, Mutters R, Korten V, Quintana A, Laeuffer JM, et al. Comparative activity of carbapenem testing: the COMPACT study. J Antimicrob Chemother 2011;66:1070-8.
80. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect 2004;10:684-704. (Pubitemid 39232684)
81. D'Arezzo S, Principe L, Capone A, Petrosillo N, Petrucca A, Visca P. Changing carbapenemase gene pattern in an epidemic multidrug-resistant Acinetobacter baumannii lineage causing multiple outbreaks in central Italy. J Antimicrob Chemother 2011;66:54-61.
82. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13, pii: 19045.
83. Gur D, Korten V, Unal S, Deshpande LM, Castanheira M. Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing Acinetobacter baumannii: report from the Turkish SENTRY Program sites. J Med Microbiol 2008;57:1529-32.
84. Wareham DW, Bean DC, Khanna P, Hennessy EM, Krahe D, Ely A, et al. Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis 2008;27:607-12.
85. Bogaerts P, Naas T, Wybo I, Bauraing C, Soetens O, Pierard D, et al. Outbreak of infection by carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-58 in Belgium. J Clin Microbiol 2006;44:4189-92. (Pubitemid 44737268)
86. Zarrilli R, Casillo R, Di Popolo A, Tripodi MF, Bagattini M, Cuccurullo S, et al. Molecular epidemiology of a clonal outbreak of multidrug-resistant Acinetobacter baumannii in a university hospital in Italy. Clin Microbiol Infect 2007;13:481-9. (Pubitemid 46566225)
87. Luna CM, Aruj PK. Nosocomial Acinetobacter pneumonia. Respirology 2007;12:787-91. (Pubitemid 350045715)
88. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005;41:848-54. (Pubitemid 41266753)
89. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309-17. (Pubitemid 39050477)
90. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006;10:R48.
91. Falagas ME, Kopterides P, Siempos II. Attributable mortality of Acinetobacter baumannii infection among critically ill patients. Clin Infect Dis 2006;43:389-90.
92. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65. (Pubitemid 26123943)
93. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41. (Pubitemid 40570245)
94. Stein A, Raoult D. Colistin: an antimicrobial for the 21st century? Clin Infect Dis 2002;35:901-2.
95. Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004;48:1586-92. (Pubitemid 38544363)
96. Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various β-lactams and β-lactam/β-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect 2005;11:24-30. (Pubitemid 40227818)
97. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010;51:79-84.
98. Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Sora M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998;42:793-802. (Pubitemid 29008082)
99. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30. (Pubitemid 34553700)
100. Jellison TK, Mckinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem - cilastatin or ampicillin - sulbactam. Pharmacotherapy 2001;21:142-8. (Pubitemid 32120147)
101. Smolyakov R, Borer A, Riesenberg K, Schlaeffer F, Alkan M, Porath A, et al. Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin - sulbactam treatment. J Hosp Infect 2003;54:32-8. (Pubitemid 38002023)
102. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003;2:321-32. (Pubitemid 37045677)
103. Garnacho J, Sole-Violan J, Sa-Borges M, Diaz E, Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med 2003;31:2478-82. (Pubitemid 37281732)
104. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005;11:115-21. (Pubitemid 40259694)
105. Enoch DA, Summers C, Brown NM, Moore L, Gillham MI, Burnstein RM, et al. Investigation and management of an outbreak of multidrugcarbapenem-resistant Acinetobacter baumannii in Cambridge, UK. J Hosp Infect 2008;70:109-18.
106. Livermore DM, Hill RL, Thomson H, Charlett A, Turton JF, Pike R, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem- and multiply-resistant Acinetobacter baumannii around London. Int J Antimicrob Agents 2010;35:19-24.
107. Consales G, Gramigni E, Zamidei L, Bettocchi D, De Gaudio AR. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J Crit Care 2011;26:453-9.
108. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, Capitano B, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31. (Pubitemid 46017915)
109. Diene SM, Bruder N, Raoult D, Rolain JM. Real-time PCR allows detection of the New Delhi metallo-β-lactamase (NDM-1)-encoding gene in France. Int J Antimicrob Agents 2011;37:544-6.
110. Espinal P, Fugazza G, López Y, Kasma M, Lerman Y, Malhotra-Kumar S, et al. Dissemination of an NDM-2-producing Acinetobacter baumannii clone in an Israeli rehabilitation center. Antimicrob Agents Chemother 2011;55:5396-8.
111. Goic-Barisic I, Towner KJ, Kovacic A, Sisko-Kraljevic K, Tonkic M, Novak A, et al. Outbreak in Croatia caused by a new carbapenem-resistant clone of Acinetobacter baumannii producing OXA-72 carbapenemase. J Hosp Infect 2011;77:368-9.
112. Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin Microbiol Infect 2009;15:588-92.
113. Culebras E, Gonzalez-Romo F, Head J, Gomez M, Morales G, Picazo JJ. Outbreak of Acinetobacter baumannii producing OXA-66 in a Spanish hospital: epidemiology and study of patient movements. Microb Drug Resist 2010;16:309-15.
114. Kohlenberg A, Brummer S, Higgins PG, Sohr D, Piening BC, de Grahl C, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii carrying the carbapenemase OXA-23 in a German university medical centre. J Med Microbiol 2009;58:1499-507.
115. Tsakris A, Ikonomidis A, Poulou A, Spanakis N, Vrizas D, Diomidous M, et al. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. Clin Microbiol Infect 2008;14:588-94. (Pubitemid 351639074)
116. Meric M, Kasap M, Gacar G, Budak F, Dundar D, Kolayli F, et al. Emergence and spread of carbapenem-resistant Acinetobacter baumannii in a tertiary care hospital in Turkey. FEMS Microbiol Lett 2008;282:214-8. (Pubitemid 351569460)
117. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J Clin Microbiol 2005;43:4826-9. (Pubitemid 41298286)
118. Poirel L, Lebessi E, Heritier C, Patsoura A, Foustoukou M, Nordmann P. Nosocomial spread of OXA-58-positive carbapenem-resistant Acinetobacter baumannii isolates in a paediatric hospital in Greece. Clin Microbiol Infect 2006;12:1138-41. (Pubitemid 44462851)
119. Heritier C, Dubouix A, Poirel L, Marty N, Nordmann P. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem- hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005;55:115-8. (Pubitemid 40192624)
120. Pérez-Pedrero MJ, Sánchez-Casado M, Rodríguez-Villar S. Nebulized colistin treatment of multi-resistant Acinetobacter baumannii pulmonary infection in critical ill patients. Med Intensiva 2011;35:226-31 [in Spanish].
121. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case - control study. Clin Infect Dis 2010;51:1238-44.
122. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83.